Online inquiry

IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3132MR)

This product GTTS-WQ3132MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C3&C4 gene. The antibody can be applied in Cardiopulmonary bypass (CPB) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000064.4; NM_001002029.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 718; 721
UniProt ID P01024; P0C0L4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3132MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1722MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ7823MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ14393MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ5535MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ12044MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ15870MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ580MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ8700MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW